MATEON THERAPEUTICS INC | Business Contracts

Convertible Promissory Note (Filed With SEC on June 27, 2022)

Independent consulting agreement between Oncotelic Therapeutics, Inc. and Seymour Fein, MD dated May 1, 2022 (Filed With SEC on May 6, 2022)

License Agreement between Oncotelic Therapeutics, Inc. and GMP Biotechnology Limited dated March 31, 2022 (Filed With SEC on April 6, 2022)

Joint Venture Agreement relating to GMP Biotechnology Limited between Dragon Overseas Capital Limited, Oncotelic Therapeutics, Inc. and GMP Biotechnology Limited dated March 31,... (Filed With SEC on April 6, 2022)

Finders Fee Agreement between Oncotelic Therapeutics, Inc. and JH Darbie & Co., Inc., dated October 26, 202 (Filed With SEC on December 1, 2021)

Windlas Mateon MOU (Filed With SEC on September 28, 2020)

Securities Purchase Agreement (Filed With SEC on June 27, 2022)

Convertible Promissory Note (Filed With SEC on June 3, 2022)

Securities Purchase Agreement (Filed With SEC on June 3, 2022)

Independent consulting agreement between Oncotelic Therapeutics, Inc. and Fatih Uckun, MD, Ph.D. dated May 1, 2022 (Filed With SEC on May 6, 2022)

License Agreement between Oncotelic Therapeutics, Inc. and Sapu Holdings, LLC dated March 31, 2022 (Filed With SEC on April 6, 2022)

Form of Convertible Promissory Note (Filed With SEC on February 2, 2022)

Form of Unsecured Convertible Note Purchase Agreement (Filed With SEC on February 2, 2022)

Form of Convertible Promissory Note (Filed With SEC on December 1, 2021)

Form of Securities Purchase Agreement (Filed With SEC on December 1, 2021)

Promissory Note issued to Golden Mountain Partners, LLC, by Oncotelic Therapeutics, Inc., dated October 25, 2021 (Filed With SEC on October 28, 2021)

Unsecured Convertible Note Purchase Agreement between Oncotelic Therapeutics, Inc. and Golden Mountain Partners, LLC, dated October 25, etween Oncotelic Therapeutics, Inc. and... (Filed With SEC on October 28, 2021)

License Agreement between Oncotelic Therapeutics, Inc. and Autotelic, Inc., dated September 30, 2021 (Filed With SEC on October 4, 2021)

Unsecured Convertible Note Purchase Agreement between Oncotelic Therapeutics, Inc. and Golden Mountain Partners, LLC, dated September 21, 2021 (Filed With SEC on September 27, 2021)

Promissory Note issued to Golden Mountain Partners, LLC, by Oncotelic Therapeutics, Inc., dated September 21, 2021 (Filed With SEC on September 27, 2021)

Term Sheet between Oncotelic Therapeutics, Inc. and Autotelic, Inc., dated August 31, 2021 (Filed With SEC on September 3, 2021)

Form of Note Purchase Agreement, dated as of August 4, 2021, by and among the Company and the investors identified therein (Filed With SEC on August 5, 2021)

Form of Convertible Promissory Note, issued by the Company under the Note Purchase Agreement dated as of August 4, 2021 (Filed With SEC on August 5, 2021)

Form of Note, dated May 25, 2021 (Filed With SEC on June 1, 2021)

Form of Subscription Agreement, dated May 25, 2021 (Filed With SEC on June 1, 2021)

Registration Rights Agreement, by and between Oncotelic Therapeutics, Inc., and Peak One Opportunity Fund, L.P., dated May 3, 2020 (Filed With SEC on May 7, 2021)

Equity Purchase Agreement by and between Oncotelic Therapeutics, Inc., and Peak One Opportunity Fund, L.P., dated May 3, 2021 (Filed With SEC on May 7, 2021)

Form of Edgepoint Warrant (Filed With SEC on March 26, 2021)

Form of Registration Rights Agreement (Filed With SEC on March 26, 2021)

Form of Note (Filed With SEC on March 26, 2021)

Form of Mateon Warrant (Filed With SEC on March 26, 2021)

Form of Subscription Agreement (Filed With SEC on March 26, 2021)

License, Development and Commercialization Agreement between Mateon Therapeutics, Inc. and Windlas Biotech Private Limited dated November 10, 2020 (Filed With SEC on November 16, 2020)

Secured Convertible Promissory Note between the Company and Golden Mountain Partners, LLC dated June 27, 2020 (Filed With SEC on November 16, 2020)

Loan, Secured Convertible Note Purchase, and Security Agreement between the Company and Golden Mountain Partners, LLC dated June 27, 2020 (Filed With SEC on November 16, 2020)

Form of Mateon Warrant, dated August 7, 2020 (Filed With SEC on August 13, 2020)

Form of Placement Agency Agreement, dated February 25, 2020 (Filed With SEC on August 13, 2020)

Form of Note, dated August 7, 2020 (Filed With SEC on August 13, 2020)

Form of Registration Rights Agreement, dated August 7, 2020 (Filed With SEC on August 13, 2020)

Form of Edgepoint Warrant, dated August 7, 2020 (Filed With SEC on August 13, 2020)

Form of Subscription Agreement, dated August 7, 2020 (Filed With SEC on August 13, 2020)

Statement of Work (Filed With SEC on August 3, 2020)

Expanded Access Program MSA (Filed With SEC on August 3, 2020)

Data Processing Agreement (Filed With SEC on August 3, 2020)

Form of Subscription Agreement, dated July 23, 2020 (Filed With SEC on July 29, 2020)

Form of Placement Agency Agreement, dated February 25, 2020 (Filed With SEC on July 29, 2020)

Form of Edgepoint Warrant, dated July 23, 2020 (Filed With SEC on July 29, 2020)

Form of Mateon Warrant, dated July 23, 2020 (Filed With SEC on July 29, 2020)

Form of Note, dated July 23, 2020 (Filed With SEC on July 29, 2020)

Registration Rights Agreement, dated July 23, 2020 (Filed With SEC on July 29, 2020)

Consulting Agreement by and between the Company and Dr. Maida, dated May 5, 2020 (Filed With SEC on June 22, 2020)

Consulting Agreement by and between the Company and Artius, dated March 9, 2020 (Filed With SEC on June 22, 2020)

NantCell Binding Termsheet (Filed With SEC on June 16, 2020)

AutotelicBIO Licensing Agreement (Filed With SEC on June 16, 2020)

Paycheck Protection Program Promissory Note dated April 21, 2020 between Mateon Therapeutics, Inc. and Silicon Valley Bank (Filed With SEC on April 27, 2020)

Research and Services Agreement (Filed With SEC on March 23, 2020)

Supplement Research and Services Agreement (Filed With SEC on March 23, 2020)

Form of Note Purchase Agreement, dated as of November 23, 2019, by and among the Company and the investors identified therein (Filed With SEC on November 25, 2019)

Employment Agreement dated August 23, 2019 between the Company and Dr. Fatih Uckun (Filed With SEC on November 25, 2019)

Form of Convertible Promissory Note, issued by the Company under the Note Purchase Agreement dated as of November 23, 2019 (Filed With SEC on November 25, 2019)

Amendment No. 1 to Agreement and Plan of Merger, dated as of November 1, 2019, by and among the Company, PointR Data, Inc. and Paris Acquisition Corp (Filed With SEC on November 12, 2019)

Agreement for Delivery and Licensed Use of WideTrial Bonus Dataset (Data License 2 Agreement) dated September 5, 2019 between WideTrial and Oncotelic (Filed With SEC on September 10, 2019)

Agreement for Delivery and Licensed Use of Data Generated from OT-101 U.S. Expanded Access (Data License 1) dated September 5, 2019 between WideTrial and Oncotelic (Filed With SEC on September 10, 2019)

Investigational Product Supply and Use Authorization Agreement for OT-101 U.S. Expanded Access (IPSUA) dated September 5, 2019 between WideTrial and Oncotelic (Filed With SEC on September 10, 2019)

Employment Agreement dated August 23, 2019 between the Company and Mr. Amit Shah (Filed With SEC on August 29, 2019)

Employment Agreement dated August 23, 2019 between the Company and Dr. Chulho Park (Filed With SEC on August 29, 2019)

Employment Agreement dated August 23, 2019 between the Company and Dr. Fatih Uckun (Filed With SEC on August 29, 2019)

Employment Agreement dated August 23, 2019 between the Company and Dr. Vuong Trieu (Filed With SEC on August 29, 2019)

Agreement and Plan of Merger, dated as of August 17, 2019, by and among the Company, PointR and Paris Acquisition Corporation (Filed With SEC on August 21, 2019)

Note Purchase Agreement between Mateon Therapeutics, Inc and PointR Data Inc. dated July 22nd, 2019 (Filed With SEC on July 24, 2019)

Convertible Promissory Note between Mateon Therapeutics, Inc and PointR Data Inc. dated July 22nd, 2019 (Filed With SEC on July 24, 2019)

Separation Agreement dated as of July 1, 2019 by and between the Company and Matthew M. Loar (Filed With SEC on July 5, 2019)

Amendment to Securities Purchase Agreement dated as of June 12, 2019 by and between the Company and Peak One Opportunity Fund, L.P (Filed With SEC on June 20, 2019)

Contingent Value Rights Agreement, dated April 17, 2019, by and among the Company, Oncotelic and American Stock Transfer and Trust Company LLC (Filed With SEC on April 25, 2019)

Separation and Release Agreement, dated April 17, 2019, by and between the Company and William D. Schwieterman, M.D (Filed With SEC on April 18, 2019)

Form of Debenture, issued by the Company to the Bridge Investors (Filed With SEC on April 18, 2019)

Form of Debenture, issued by the Company to PeakOne (Filed With SEC on April 18, 2019)

Form of Securities Purchase Agreement, dated as of April 17, 2019, by and among the Company and PeakOne (Filed With SEC on April 18, 2019)

Form of Securities Purchase Agreement, dated as of April 17, 2019, by and among the Company and the Bridge Investors (Filed With SEC on April 18, 2019)

Agreement and Plan of Merger, dated as of April 17, 2019, by and among the Company, Oncotelic and Oncotelic Acquisition Corporation (Filed With SEC on April 18, 2019)

MATEON THERAPEUTICS INC (81)